Navigation Links
Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
Date:11/18/2013

Irvine, CA - (PRWEB) November 18, 2013

Proove Biosciences, the leading personalized pain medicine laboratory, will be exhibiting and presenting clinical data and research at the National Workers’ Compensation and Disability Conference Expo. This industry-leading event attracts thousands of workers’ compensation and disability management professionals from around the country, and will be hosted at the Mandalay Bay Hotel, in Las Vegas November 20-22, 2013.

The NWCD Conference allows professionals to receive guidance and insight on new trends from experts spanning all spectrum of the industry. This year’s event will contain a brand new track on disability management solutions, sessions devoted to critical issues in trendsetting states which typically affect associated regions, and an emphasis on technology, innovation and research.

Proove Biosciences has been presenting research and findings at pain medicine scientific meetings across the country in 2013, and will now have the opportunity to present to the case managers, claims managers, health and safety professionals, legislators, and other workers compensation and disability claims personnel in attendance. This year’s emphasis on technology and innovation aligns perfectly with Proove’s mission and capacity in delivering scientific proof towards reducing costs and improving outcomes of workers compensation claims.

“Workers compensation and disability claims are a huge cost driver in this industry, in larger part because of medical abuse and dependence that stems from a gap in understanding a patient's individual genetic profile,” stated Proove Biosciences President and Founder, Brian Meshkin. “We are the only company providing proprietary testing services in personalized pain medicine, and the only company with data specifically on genetics and pain medicine. We are happy and excited to exhibit our work at the NWCD and help inform professionals on how we can all lower risk, costs, and improve patient and worker health.”

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/11/prweb11333081.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree
5. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
6. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... The Academy of Model Aeronautics (AMA) ... Model Aviation Day will take place from 9 a.m. to 2 p.m. at the ... for all ages. , Aviation Adventure Day will be packed with entertaining activities for ...
(Date:7/17/2017)... ... July 17, 2017 , ... OHAUS Corporation, a leading worldwide ... its new line of Heavy-Duty Orbital Shakers today. , Eight New Models Available, ... laboratory applications. These shakers are ideal for load capacities from 35 to ...
(Date:7/17/2017)... ... July 17, 2017 , ... Panitch ... recently participated in the BiG (Biomedical Innovation Group) annual meeting in China. , ... CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing highly personalized anti-cancer technology ...
(Date:7/17/2017)... ... 17, 2017 , ... DuPont Pioneer today announced the launch ... (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists is now available ... biologicals and digital solutions. , “DuPont Pioneer is building on its long history ...
Breaking Biology Technology:
(Date:4/5/2017)... YORK , April 5, 2017 Today ... is announcing that the server component of the HYPR ... known for providing the end-to-end security architecture that empowers ... HYPR has already secured over 15 million ... makers including manufacturers of connected home product suites and ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):